Dry Powder Inhaler Devices Market Research Report-Ken Research

1
The Emerging Dry Powdered Inhaler Market Outlook
Ken Research
2
According to the study, Dry Powder Inhaler
Devices - Medical Devices Pipeline Assessment,
2018, Some companies operating in this industry
along with their products are Acorda Therapeutics
Inc, CVT-427 Drug Delivery Device Aespira Ltd.,
resQhaler Bayer AG, Ciprofloxacin Dry Powder
Inhaler Bespak Europe Ltd, DEV610 DPI
Boehringer Ingelheim GmbH, Next Generation
Respimat Inhaler Circassia Pharmaceuticals Plc,
Tiotropium bromide DPI GlaxoSmithKline Plc,
Gemini Multi-Dose Combination Inhaler MannKind
Corp, Dreamboat MannKind Corp, Treprostinil
Technosphere Respira Therapeutics Inc, RT234 AOS
DPI Sandoz International GmbH, Solis Multi-Dose
Dry Powder Inhaler Sun Pharma Advanced Research
Company Ltd, SPARC DPI Verona Pharma Plc, RPL554
- Dry Powder Inhaler. Dry powdered inhalers
(DPIs) are widely accepted inhaler devices
primarily used in Europe where it is often used
to treat chronic obstructive pulmonary and
asthma. The acceptance of these devices in the
United States can be primarily correlated to
introduction of 2 well known drugs. These are
Advair Diskus and Serevent Diskus. The prime
advantage of DPIs is that it offers convenience
to consumers especially for combination
therapies. The design, development and formation
of any powder drug delivery system is a very
complex task. The key is to match device geometry
with the choice of formulation. Good quality
aerosol in terms of aerosols aerodynamic
particle size is one of the most important
factors in pulmonary delivery from DPI.
3
There are primarily 2 types of dry powdered
inhalers currently. One in which drug is packaged
in a gelatin blister or foil capsule and the
other in which there is a reservoir of drug from
which doses are metered out. These devices are
becoming relatively popular as they do not
require chlorofluorocarbon propellant to spread
the drug which makes these devices eco friendly.
The efficiency of these devices to in dispersion
of the aerosol is also a key factor that leads to
their huge success. Other benefits include
reduced need for patient coordination, less
potential for formulation problems. Environmental
factors especially humidity and temperature also
affect the functionality of these
devices. Recent developments in this industry
include focus on delivery system that
disaggregates the powder as this effectively
minimizes formulation development work. The
current devices that are in use are too bulky and
heave that limits mobility. Companies are trying
to develop devices that are much smaller in
design and simultaneously ensuring that the
efficiency does not go down. A multi dose
reservoir has been developed that can be used for
the delivery of formoterol. One of the most
recent developments is the breezhaler device.
This is a single dose DPI which functions on
aerolizer technology with many design changes
which ensure device handling. Capsules containing
acting beta-adrenergic bronchodilator indacaterol
maleate and the long-acting muscarinic antagonist
glycopyrronium are used by this device to deliver
the drug. This device has been structured in a
manner to lower the internal airflow resistance.
4
In the last decade, the world has witnessed
increasing usage of dry powdered inhaler devices
primarily because of their efficiency and eco
friendly nature. The future of this industry
shall focus more on consistence, reliability,
efficiency and mobility. All these factors shall
ensure greater penetration of DPIs especially in
the developing markets. The growth potential for
these devices is definitely high which could be
tapped if the manufacturers are able to keep up
with improvements in pharmaceutical industries
also. For More Information, Refer to the Link
below- https//www.kenresearch.com/healthcare/med
ical-devices/dry-powder-inhaler-devices/151035-91.
html Related Report https//www.kenresearch.com/
healthcare/pharmaceuticals/dry-powder-inhaler-devi
ces-medical-devices/22726-91.html Contact
UsKen ResearchAnkur Gupta, Head Marketing
CommunicationsSales_at_kenresearch.com91-901537824
9  
5
(No Transcript)